



(12) Translation of
European patent specification

(11) NO/EP 2894165 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/18 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2023.03.20	
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.01.04	
(86)	European Application Nr.	15152757.9	
(86)	European Filing Date	2009.11.10	
(87)	The European Application's Publication Date	2015.07.15	
(30)	Priority	2008.11.10, US, 198803 P 2008.11.18, US, 199562 P 2008.11.18, US, 199563 P 2008.11.18, US, 199569 P 2008.11.19, US, 199764 P	2008.12.01, US, 200634 P 2008.12.01, US, 200635 P 2008.12.01, US, 200640 P 2009.05.28, US, 181788 P 2009.07.23, US, 228047 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR	
	Designated Extension States:	AL ; BA ; RS	
(73)	Proprietor	ALEXION PHARMACEUTICALS, INC., 121 Seaport Boulevard, Boston, MA 02210, USA	
(72)	Inventor	Rother, Russell, P., 10325 Forest Meadow Drive, Oklahoma City, OK 73151, USA Bedrosian, Camille, 22 Lantern Road, Belmont, MA 02478, USA Squinto, Stephen, P., 16 Coachmans Lane, Bethnay, CT 06524, USA Bell, Leonard, 59 Tumblebrook Road, Woodbridge, CT 06525, USA	
(74)	Agent or Attorney	RWS, Europa House, Chiltern Park, Chiltern Hill, SL99FG CHALFONT ST PETER, Storbritannia	

(54)	Title	Methods and compositions for treating complement-associated disorders
(56)	References Cited:	US-A1- 2005 191 298 REINHARD WÜRZNER AND LOTHAR ZIMMERHACKL: "Therapeutic strategies for atypical and recurrent hemolytic uremic syndromes (HUS)", 1 January 2006 (2006-01-01), COMPLEMENT AND KIDNEY DISEASE,, PAGE(S) 149 - 163, XP009161632, * page 159, paragraph 3 - page 160, paragraph 1 * DAVID KAVANAGH ET AL: "Complement Regulatory Genes and Hemolytic Uremic Syndromes", ANNUAL REVIEW OF MEDICINE, vol. 59, no. 1, 1 February 2008 (2008-02-01), pages 293-309, XP055186136, ISSN: 0066-4219, DOI: 10.1146/annurev.med.59.060106.185110 HILLMEN P ET AL: "EFFECT OF Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemaglobinuria", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 350, no. 6, 5 February 2004 (2004-02-05), pages 552-559, XP009057948, ISSN: 1533-4406, DOI: 10.1056/NEJM0A031688

Anonymous: "Atypical hemolytic uremic syndrome - Wikipedia", wikipedia, 20 December 2016 (2016-12-20), XP055330648, Retrieved from the Internet:
 URL: https://en.wikipedia.org/wiki/Atypical_hemolytic_uremic_syndrome [retrieved on 2016-12-20]

RICKLIN DANIEL ET AL: "Complement-targeted therapeutics", NATURE BIOTECHNOLOGY, GALE GROUP INC, US, vol. 25, no. 11 1 November 2007 (2007-11-01), pages 1265-1275, XP002546813, ISSN: 1087-0156, DOI: 10.1038/NBT1342 Retrieved from the Internet:
 URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966895/> [retrieved on 2007-11-07]

Anonymous: "Assessment report Soliris eculizumab Procedure No.: EMEA/H/C/000791/II/0027", 22 September 2011 EXT/834951/2011 Corr1 Committee for Medicinal Products for Human Use (CHMP), 1 January 2015 (2015-01-01), page 5555, XP055493808, Retrieved from the Internet:
 URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000791/WC500119185.pdf [retrieved on 2018-07-19]

CHATELET V ET AL: "Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.", AMERICAN JOURNAL OF TRANSPLANTATION : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF TRANSPLANTATION AND THE AMERICAN SOCIETY OF TRANSPLANT SURGEONS NOV 2009, vol. 9, no. 11, November 2009 (2009-11), pages 2644-2645, XP002739219, ISSN: 1600-6143

"More on Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome", NEW ENGLAND JOURNAL OF MEDICINE, vol. 360, no. 20, 14 May 2009 (2009-05-14), pages 2142-2143, XP055186122, ISSN: 0028-4793, DOI: 10.1056/NEJMc090453

CHANTAL LOIRAT ET AL: "Complement and the atypical hemolytic uremic syndrome in children", PEDIATRIC NEPHROLOGY ; JOURNAL OF THE INTERNATIONAL PEDIATRIC NEPHROLOGY ASSOCIATION, SPRINGER, BERLIN, DE, vol. 23, no. 11, 2 July 2008 (2008-07-02), pages 1957-1972, XP019658955, ISSN: 1432-198X, DOI: 10.1007/S00467-008-0872-4

HILLMEN PETER ET AL: "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 355, no. 12, 21 September 2006 (2006-09-21), pages 1233-1243, XP002482088, ISSN: 1533-4406, DOI: 10.1056/NEJMOA061648

JENS NÜRNBERGER ET AL: "Eculizumab for Atypical Hemolytic-Uremic Syndrome", NEW ENGLAND JOURNAL OF MEDICINE, vol. 360, no. 5, 29 January 2009 (2009-01-29), pages 542-544, XP055045531, ISSN: 0028-4793, DOI: 10.1056/NEJMc0808527

A. AVILA ET AL: "Remission of aHUS neurological damage with eculizumab", CLINICAL KIDNEY JOURNAL, vol. 8, no. 2, 22 January 2015 (2015-01-22), pages 232-236, XP055394181, ISSN: 2048-8505, DOI: 10.1093/ckj/sfu144

GILLIAN M. KEATING: "Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome", DRUGS, vol. 73, no. 18, 1 December 2013 (2013-12-01), pages 2053-2066, XP055493804, NZ ISSN: 0012-6667, DOI: 10.1007/s40265-013-0147-7

CHATELET VALERIE ET AL: "Efficacy of Eculizumab in a Plasmapheresis-Dependent Patient with Atypical Hemolytic Uremic Syndrome with C3 Mutation Following Plasmapheresis Withdrawal", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 112, no. 11, 16 November 2008 (2008-11-16), page 4579, XP086679334, ISSN: 0006-4971, DOI: 10.1182/BLOOD.V112.11.4579.4579

RALPH A. GRUPPO ET AL: "Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome", NEW ENGLAND JOURNAL OF MEDICINE, vol. 360, no. 5, 29 January 2009 (2009-01-29), pages 544-546, XP055186116, ISSN: 0028-4793, DOI: 10.1056/NEJMc0809959

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Antistoff for anvendelse ved behandling av atypisk hemolytisk uremisk syndrom (aHUS) hos en pasient, hvori antistoffet er eculizumab.